Premium
Primary cutaneous B‐cell lymphoma: A unique type of low‐grade lymphoma. Clinicopathologic and immunologic study of 83 cases
Author(s) -
Santucci Marco,
Pimpinelli Nicola,
Arganini Luisa
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910501)67:9<2311::aid-cncr2820670918>3.0.co;2-0
Subject(s) - medicine , pathology , lymphoma , malignancy , immunophenotyping , cutaneous lymphoma , cd5 , antigen , immunology , mycosis fungoides
The clinical presentation and course, and the morphoimmunologic features of primary cutaneous B‐cell lymphoma (CBCL) were investigated in a series of 83 patients. Fifty‐one patients were male and 32 were female (male‐to‐female ratio of 1.6:1); CBCL primarily involved the elderly (median age, 58 years). A locoregional extension of the disease was quite frequent (86.7%). The neoplastic cells showed a range of appearances reminiscent of the whole spectrum of follicular/parafollicular cells. The antigenic phenotype of tumor cells (CD19+, CD20+, CD22+, CD28+, CD10−, CD5−, MB2+, CD74+/−, CDw75+/−. MT2+/−, surface immunoglobulin+ monoclonal/−) plus the presence of admixed CD14‐ dendritic reticulum cells suggest a mantle‐zone nature for CBCL. The nonaggressive clinical behavior with a substantial tendency to remain localized to a limited area of the skin, the quite good response to nonaggressive treatment, and the dichotomy existing between the enhancement of morphoimmunologic atypism—which parallels the increasing age and growth rate of lesions—and the constant benign overall prognosis on long‐term follow‐up make CBCL a unique type of lymphoma of low‐grade malignancy. Proper recognition of CBCL is mandatory to avoid possible undertreatment or overtreatment of the patients affected.